Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05042791
Recruitment Status : Recruiting
First Posted : September 13, 2021
Last Update Posted : March 2, 2022
Sponsor:
Information provided by (Responsible Party):
Jiangxi Provincial Cancer Hospital

Brief Summary:
This study evaluates the efficacy and safety of SRT combined with pyrotinib and capecitabine in the treatment of patients with HER2-positive advanced breast cancer patients with brain metastases.

Condition or disease Intervention/treatment Phase
HER2-positive Metastatic Breast Cancer Combination Product: radiation combined with pyrotinib and capecitabine Phase 2

Detailed Description:
Brain metastases occur in 30-50% of patients with metastatic HER2-positive breast cancer. In the case of multiple brain metastases, radiation therapy is the preferred therapeutic approaches. However, the side effects of WBRT for long-lived patients are also obvious, such as irreversible decline in cognitive function and decline in memory function. WBRT can also cause extensive hair loss and extensive white matter lesions on imaging. Pyrotinib as an oral tyrosine kinase inhibitor has good efficacy and safety in patients with breast cancer brain metastases. Therefore, in order to reduce the impact of WBRT on the cognitive function, a phase II clinical study of SRT versus WBRT combined with pyrotinib and capecitabine in the treatment of MBC with brain metastases was carried out to explore the efficacy and safety of radiotherapy de-escalation therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 362 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SRT Versus WBRT Combined With Pyrrotinib and Capecitabine in the Treatment of HER2-positive Advanced Breast Cancer Patients With Brain Metastases: A Randomized Controlled, Prospective Clinical Study
Estimated Study Start Date : March 1, 2022
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : September 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: SRT combined with pyrotinib and capecitabine

SRT: SRT needs to be comprehensively considered based on the size, number, and location of the lesion, and SRS and FSRT are performed according to clinical needs.

Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.

Combination Product: radiation combined with pyrotinib and capecitabine
This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases

Active Comparator: WBRT combined with pyrotinib and capecitabine

WBRT: WBRT need to be considered based on the size, number, and location of the lesion.

Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.

Combination Product: radiation combined with pyrotinib and capecitabine
This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases




Primary Outcome Measures :
  1. CNS-ORR [ Time Frame: Estimated up to 1 year ]
    Objective response rate of central nervous system



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age> 18 years old, female
  2. KPS≥70
  3. HER2-positive breast cancer is confirmed by the pathology laboratory with an immunohistochemical (IHC) score of 3+ and/or 2+ and a positive in situ hybridization (ISH) test (ISH amplification rate ≥ 2.0)
  4. Brain metastasis confirmed by MRI, in line with the indications for whole brain radiotherapy
  5. At least one measurable brain lesion exists according to the RECIST 1.1 standard
  6. Unlimited number of previous chemotherapy lines
  7. Have not used capecitabine in the past, or progressed 6 months after capecitabine stopped, or progressed after capecitabine as adjuvant therapy stopped for one year
  8. The expected survival period is more than 12 weeks
  9. Patients must have adequate organ function, criteria as follows.

    1. Blood routine examination:Absolute Neutrophil Count (ANC)≥1.5×109/L;PLT ≥100×109/L; Hb ≥90g/L
    2. Blood chemistry test:TBIL ≤1.5 times the upper limit of normal (ULN); ALT and AST≤3 times ULN; For patients with liver metastases, ALT and AST≤5×ULN; BUN and Cr≤1×ULN and creatinine clearance ≥50mL/min (CockcroftGault formula);
    3. Ultrasonic cardiogram: LVEF≥50%
    4. 12-lead ECG: The QT interval (QTcF) corrected by Fridericia's method is < 470 ms
  10. Patients with known hormone receptor status
  11. Patients need to voluntarily join this study after they fully understand and sign the informed consent form. Patients need to have good compliance and be willing to cooperate with follow-up.

Exclusion Criteria:

  1. Patients with brain metastases with extensive meningeal metastasis
  2. Brain metastases within 5 mm of the hippocampus
  3. There are many factors that affect the administration and absorption of drugs, for example: inability to swallow, chronic diarrhea and intestinal obstruction
  4. Those who have received chemotherapy, surgical treatment (excluding local puncture) or molecular targeted therapy within 4 weeks before enrollment; those who have received anti-tumor endocrine therapy after the screening period
  5. Participated in other drug clinical trials within 4 weeks before enrollment
  6. Have used or are currently using HER2 tyrosine kinase inhibitors (lapatinib, niratinib, pyrotinib, etc.)
  7. Suffered from other malignant tumors in the past 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma
  8. Receive any other anti-tumor therapy at the same time
  9. Those who are known to have a history of allergies to the drug; have a history of immunodeficiency, including positive HIV tests, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases, or organ transplants history
  10. Have ever suffered from any heart disease, including: (1) arrhythmia requiring medication or clinical significance; (2) myocardial infarction; (3) heart failure; (4) anyone judged by the researcher as unsuitable for participation becase of other heart diseases in this trial, etc.
  11. Female patients during pregnancy and lactation, female patients with fertility and a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period
  12. According to the judgment of the investigator, there are accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study (including but not limited to severe hypertension that cannot be controlled by drugs, severe diabetes, active infection, etc.)
  13. The patient has not recovered from the toxicity of the previous treatment to grade 0-1 (except for hair loss)
  14. Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia
  15. Concomitant use of CYP3A4 inhibitors or inducers or drugs that prolong the QT interval
  16. Any other circumstances that are not suitable for inclusion in this study (investigator assessment)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05042791


Contacts
Layout table for location contacts
Contact: Chunling no Jiang, Dr. +86 13979109200 jclil2002@163.com

Locations
Layout table for location information
China, Jiangxi
Jiangxi Cancer Hospital of Nanchang University Recruiting
Nanchang, Jiangxi, China, 330029
Contact: Chunling Jiang, MD,PHD    +8613979109200    jclil2002@163.com   
Sponsors and Collaborators
Jiangxi Provincial Cancer Hospital
Investigators
Layout table for investigator information
Principal Investigator: Chunling Jiang Jiangxi Provincial Cancer Hospital
Layout table for additonal information
Responsible Party: Jiangxi Provincial Cancer Hospital
ClinicalTrials.gov Identifier: NCT05042791    
Other Study ID Numbers: 20210901-jiangchunling
First Posted: September 13, 2021    Key Record Dates
Last Update Posted: March 2, 2022
Last Verified: February 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Brain Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Capecitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents